Search Results - "Bolli, G.B."

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in insulin- naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial by Bolli, G.B, Riddle, M.C, Bergenstal, R.M, Wardecki, M, Goyeau, H, Home, P.D

“…Abstract Aim To explore if efficacy and safety findings for insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100), observed over…”
Get full text

Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension) by Terauchi, Y, Koyama, M, Cheng, X, Sumi, M, Riddle, M.C, Bolli, G.B, Hirose, T

“…Abstract Aims To compare insulin glargine 300 U/mL (Gla-300) with glargine 100 U/mL (Gla-100) in Japanese adults with uncontrolled type 2 diabetes on basal…”
Get full text

Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus by Owens, D.R, Monnier, L, Bolli, G.B

“…Abstract Metabolic consequences of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the result of enhanced glucose-stimulated insulin secretion,…”
Get full text

GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials by Porcellati, F, Lucidi, P, Bolli, G.B, Fanelli, C.G

“…Abstract The add-on of a prandial (short-acting) GLP-1 RA to basal insulin in subjects with T2DM who fail to control A1C on basal insulin, stems from the…”
Get full text

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application by Owens, D R, Bolli, G B

“…The new rDNA and DNA-derived "basal" insulin analogs, glargine and detemir, represent significant advancement in the treatment of diabetes compared with…”
Get more information

The new long-acting insulin glargine U300 achieves an early steady state with low risk of accumulation by Monnier, L, Owens, D.R, Bolli, G.B

Get full text

Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes by Lucidi, P, Porcellati, F, Marinelli Andreoli, A, Candeloro, P, Cioli, P, Bolli, G.B, Fanelli, C.G

“…Abstract Aims This study measured the insulin concentration (Ins[C] ) of NPH insulin in vials and cartridges from different companies after either resuspension…”
Get full text

Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study by Lucidi, P, Porcellati, F, Candeloro, P, Cioli, P, Marinelli Andreoli, A, Marzotti, S, Schmidt, R, Bolli, G.B, Fanelli, C.G

“…Abstract Background and aims After subcutaneous injection insulin glargine is rapidly metabolized to M1 and M2. In vitro , both M1 and M2 have metabolic…”
Get full text

Early insulin treatment in type 2 diabetes: ORIGINal sin or valuable choice as ORIGINal treatment? An open debate on the ORIGIN study results by Bolli, G.B, Consoli, A, Giaccari, A

“…Abstract Diabetes is ultimately the result of relative or absolute insulin deficiency; insulin should therefore represent its “natural” treatment, from the…”
Get full text

Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes by Bolli, G.B, Songini, M, Trovati, M, Del Prato, S, Ghirlanda, G, Cordera, R, Trevisan, R, Riccardi, G, Noacco, C

“…Abstract Background and aims To compare switching from NPH insulin (NPH) to insulin glargine (glargine) with continuing NPH for changes in fasting blood…”
Get full text

Physical characteristics that predict final basal insulin dose in type 2 diabetes mellitus, with a special focus on BMI by Simon, A.C.R, Bolli, G.B, Dain, M.-P, Wang, E, Holleman, F

“…Abstract Background and aims The possibility to predict final insulin dose based on patient's characteristics would allow for efficient titration for patients…”
Get full text

Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women by Torlone, E, Gennarini, A, Ricci, N. Busciantella, Bolli, G.B

Get full text

IDF2022-1166 Response to glargine U-100 initiation in new subgroups of type 2 diabetes replicated in randomised controlled trials by Landgraf, W., Bigot, G., Frier, B.M., Bolli, G.B., Owens, D.R.

Get full text

Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes by Bailey, T.S., Pettus, J., Roussel, R., Schmider, W., Maroccia, M., Nassr, N., Klein, O., Bolli, G.B., Dahmen, R.

Get full text

Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) – a review of evidence and clinical interpretation by Owens, D.R., S Bailey, T., Fanelli, C.G., Yale, J.-F., Bolli, G.B.

“…Second-generation basal insulin analogues (e.g. insulin degludec, insulin glargine 300 U/mL), were designed to further extend the duration of insulin action…”
Get full text

Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes by Yale, J.-F., Aroda, V.R., Charbonnel, B., Sinclair, A.J, Trescoli, C., Cahn, A., Bigot, G., Merino-Trigo, A., Brulle-Wohlhueter, C., Bolli, G.B., Ritzel, R.

“…Older people with type 2 diabetes (T2DM) are at an increased risk of hypoglycaemia and its consequences. However, efficacy and safety data for basal insulin…”
Get full text

Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure by Chiriacò, Martina, Tricò, Domenico, Leonetti, Simone, Petrie, John R., Balkau, Beverley, Højlund, Kurt, Pataky, Zoltan, Nilsson, Peter M, Natali, Andrea

“…The pathophysiological link between adiposity and blood pressure is not completely understood, and evidence suggests an influence of sex and genetic…”
Get full text

Italian Titration Approach Study (ITAS) with insulin glargine 300 U/mL in insulin-naïve type 2 diabetes: Design and population by Bonadonna, R.C., Giaccari, A., Buzzetti, R., Aimaretti, G., Cucinotta, D., Avogaro, A., Perseghin, G., Larosa, M., Bolli, G.B., Fanelli, C.G.

“…Fostering patient's self-managing of basal insulin therapy could improve glucose control, by removing patient's and physician's barriers to basal insulin…”
Get full text

Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial by Bolli, G.B., Riddle, M.C., Bergenstal, R.M., Wardecki, M., Goyeau, H., Home, P.D.

“…To explore if efficacy and safety findings for insulin glargine 300U/mL (Gla-300) versus insulin glargine 100U/mL (Gla-100), observed over 6 months in…”
Get full text

Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events by Riddle, M.C., Bolli, G.B., Avogaro, A., Gimenez Álvarez, M., Merino-Trigo, A., Boëlle-Le Corfec, E., Home, P.D.

“…To describe in type 2 diabetes the 24-hour distribution of hypoglycaemia and compare the frequency of nocturnal events based on a predefined nocturnal window…”
Get full text